

Supplementary Table 2: Overview of culture conditions.

Cell line	Medium	Cells/well
CHLA-01-MED	DMEM/F-12, 2 % B-27 supplement, 20 ng/mL EGF, 20 ng/mL FGF	10000
CHLA-01R-MED	DMEM/F-12, 2 % B-27 supplement, 20 ng/mL EGF, 20 ng/mL FGF	10000
D283 MED	MEM, 10 % FBS, 1 % P/S,	5000
D341 MED	MEM, 20 % FBS	5000
D425 MED	Modified IMEM, 10 % FBS, 1 % P/S	2500
D425 MED (for <i>in vivo</i>)	1:1 DMEM/F-12 and Neural Basal Medium A, 1 % P/S, 1 % L-Glutamine, 1 mM Sodium pyruvate, 0.025 mM HEPES 1 % MEM NEAA 2 % B-27, 10 ng/mL EGF, FGF and LIF, 0.4 mg/mL Heparin	-
MED8A	DMEM, 10 % FBS, 1 % P/S	2000
MED8A (for <i>in vivo</i>)	DMEM, 10 % FBS, 1 % P/S, 1 % Glutamax	-
HD-MB03	RPMI 1640, 10 % FBS, 1 % MEM NEAA	4000
MB3W1	DMEM/F-12, 0.4 % P/S, 2 % B-27, 1 % MEM Vitamin, 20 ng/mL EGF and FGF	4000
MB002	1:1 DMEM/F-12 and Neural Basal Medium A, 1 % P/S, 1 % L-Glutamine, 1 mM Sodium pyruvate, 0.025 mM HEPES 1 % MEM NEAA 2 % B-27, 10 ng/mL EGF, FGF and LIF, 0.4 mg/mL Heparin	10000
CHLA-259	IMDM, 20 % FBS, 1x IST	9000
Daoy	DMEM, 10 % FBS, 1 % P/S	1000
ONS76	DMEM, 10 % FBS, 1 % P/S	1000
UW-228-2	DMEM, 10 % FBS, 1 % P/S	750
UW-228-3	DMEM, 10 % FBS, 1 % P/S	1000
ATRT13808	1:1 DMEM/F-12 and Neural Basal Medium A, 1 % P/S, 1 % L-Glutamine, 1 mM Sodium pyruvate, 0.025 mM HEPES 1 % MEM NEAA 2 % B-27, 10 ng/mL EGF, FGF and LIF, 0.4 mg/mL Heparin	3500
BT-12	IMDM, 20 % FBS, 1x IST	1500
BT-16	IMDM, 20 % FBS, 1x IST	3500
CHLA-02-ATRT	DMEM/F-12, 2 % B-27 supplement, 20 ng/mL EGF, 20 ng/mL FGF	5000
CHLA-04-ATRT	DMEM/F-12, 2 % B-27 supplement, 20 ng/mL EGF, 20 ng/mL FGF	4000
CHLA-05-ATRT	DMEM/F-12, 2 % B-27 supplement, 20 ng/mL EGF, 20 ng/mL FGF	9000
CHLA-06-ATRT	DMEM/F-12, 2 % B-27 supplement, 20 ng/mL EGF, 20 ng/mL FGF	6500
CHLA-266	IMDM, 20 % FBS, 1x IST	4000
HHU-ATRT-01	Neurocult medium, 1 % L-Glutamine, 1 % P/S, 75 µg/mL BSA, 1 % N-2 supplement, 2 % B-27 supplement, 10 ng/mL EGF, 10 ng/mL FGF, Heparin	3500
JC-ATRT	1:1 DMEM/F-12 and Neural Basal Medium A, 1 % P/S, 1 % L-Glutamine, 1 mM Sodium pyruvate, 0.025 mM HEPES 1 % MEM NEAA 2 % B-27, 10 ng/mL EGF, FGF and LIF, 0.4 mg/mL Heparin	7000
VU397	1:1 DMEM/F-12 and Neural Basal Medium A, 1 % P/S, 1 % L-Glutamine, 1 mM Sodium pyruvate, 0.025 mM HEPES 1 % MEM NEAA 2 % B-27, 10 ng/mL EGF, FGF and LIF, 0.4 mg/mL Heparin	4500
AM-38	MEM, 20 % FBS, 1 % L-Glutamine	4000
LN-18	DMEM, 10 % FBS, 1 % P/S	1250
LN-308	DMEM, 10 % FBS, 1 % P/S	1750
LN-229	DMEM, 10 % FBS, 1 % P/S	1000
SJ-GBM2	IMDM, 20 % FBS, 1x IST	1500
T98G	DMEM, 10 % FBS, 1 % P/S	1250
TP365MG	DMEM, 10 % FBS, 1 % P/S	1250
U138MG	DMEM, 10 % FBS, 1 % P/S	3000

U251MG	DMEM, 10 % FBS, 1 % P/S	1250
U87MG	DMEM, 10 % FBS, 1 % P/S	2000
YH-13	MEM, 20 %FBS, 1 % L-Glutamine	4000

Gibco DMEM (#31966-021); DMEM/F-12 (#11320-033); MEM (#10370-047); Modified IMEM (#A10489-01); RPMI (#31870-025); IMDM (#12440-061); Neurobasal-A Medium (#10888022) B-27 supplement, minus vitamin A (#12587010); L-Glutamine (#25030-024); MEM Vitamin Solution (#11120037); MEM Non-Essential Amino Acid (NEAA) Solution (#1140-035); Sodium bicarbonate (#25080-094); Sodium pyruvate (#11360-070); HEPES (#15630-080) BSA Fraction V (7.5 % solution) (#15260-037); Insulin-Transferrin-Selenium (IST) (#41400-045); N-2 supplement (#17502048); EGF Human Recombinant Protein (#PHG0311) was purchased from Thermo Fisher. NeuroCult NS-A Basal Medium (Human) (#05750) and Heparin Solution (0.2 %) (#07980) were purchased from Stemcell Technologies (Köln, Germany). Penicillin-Streptomycin (P/S) (#P4333) and heat inactivated Fetal Bovine Serum (FBS) (#F9665) were purchased from Sigma-Aldrich. Fibroblast Growth Factor basic, human recombinan) was purchased from biomol (#50361.50, Hamburg, Germany). Leukemia Inhibitory Factor human (#LIF1010) was purchased from Millipore.